TrialThe journal of headache and pain2026

Long-term safety and continued clinical benefit of erenumab 70 mg in Asian patients with chronic migraine: an open-label extension of the phase 3 DRAGON study.

Shengyuan Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.